Triethylamine → (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide

HRID 1482995노트

반응식

HRID 1482995 반응식
[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:34])=[O:33])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:27])([F:26])[F:25])[C:21]([C:28]([OH:30])=O)=[CH:20][N:19]=4)[C@H:14]([CH:15]([CH3:17])[CH3:16])[C:9]3=[N:8][C:7]=2[CH:31]=1.C[N:37](C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CC[N:62](CC)CC.[NH4+].[Cl-]>CN(C=O)C.O>[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:33])=[O:34])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:25])([F:27])[F:26])[C:21]([C:28]([NH2:37])=[O:30])=[CH:20][N:19]=4)[C@H:14]([CH:15]([CH3:16])[CH3:17])[C:9]3=[N:8][C:7]=2[CH:31]=1.[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:33])=[O:34])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:25])([F:27])[F:26])[C:21]([C:28]([NH2:62])=[O:30])=[CH:20][N:19]=4)[C@@H:14]([CH:15]([CH3:16])[CH3:17])[C:9]3=[N:8][C:7]=2[CH:31]=1

참가 물질

8

반응물 4

HCID 8471TriethylamineHCID 25517Ammonium ChlorideHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 71736481(R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid

생성물 2

HCID 71736631(R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide수율 56.7%HCID 71736632(S)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide수율 10.8%

시약·촉매·용매 2

HCID 962Water용매HCID 6228Dimethylformamide용매

실험 절차

To a solution of (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid (100 mg, 0.19 mmol, partially racemized) in DMF (2 mL) was added HATU (97 mg, 0.25 mmol) and Et3N (52 mg, 0.51 mmol). The mixture was stirred at rt for 1 h. NH4Cl (19 mg, 0.34 mmol) was added in one portion. The mixture was stirred at rt for 16 h. Water (10 mL) was added and the aqueous layer was extracted with EtOAc (4×10 mL). The combined organic layers were washed with water (3×10 mL) and brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by preparative TLC and SFC separation to afford (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide (55.2 mg, 56.7% yield, isomer 1) as a white solid and (S)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide (10.5 mg, 10.8% yield, isomer 2) as white solid.

후처리

  1. stirringThe mixture was stirred at rt for 16 h
  2. extractionthe aqueous layer was extracted with EtOAc (4×10 mL)
  3. washThe combined organic layers were washed with water (3×10 mL) and brine
  4. dry with materialdried over anhydrous Na2SO4
  5. filtrationfiltered
  6. concentrationconcentrated under vacuum
  7. customThe residue was purified by preparative TLC and SFC separation

출처 및 근거

ORD 기록
ord-c4576e83d9624c7994838cd7cab2781b
출처 데이터셋
uspto-grants-2016_08
특허 번호
US09416135B2

반응 노트

불러오는 중…